Scott Isaacs, MD, FACP, FACEs Post Reduced-frequency GLP-1 as a maintenance strategy: in this case series, patients who tapered from weekly semaglutide/tirzepatide to less frequent dosing maintained weight loss, body composition, and metabolic syndrome gains, supporting structured de-escalation to lower burden without sacrificing efficacy
Ive watched this pattern repeat at multiple sites: once O + BAC is tested, the pathway to reuse becomes clearer
Real results from a clinician who takes time to know you
The currently available incretin-based therapies are listed in Table 1 , and their physiologic effects are summarized in Figure 1
[DOI] [PubMed] [Google Scholar] 62.Lake AC, Sun Y, Li JL, Kim JE, Johnson JW, et al
Variety remains a favorite talking point for reel enthusiasts